Equine Rhinopneumonitis Virus

Details Equine Rhinopneumonitis Virus Equine Rhinopneumonitis Virus

1976-04-23

1978-08-29

Rosen, Sam

Drug, bio-affecting and body treating compositions

Lymphokine

195 13, A61K 3912, C12K 700

Patent

active

041104331

ABSTRACT:
A virulent strain of Equine Rhinopneumonitis (ERP) Virus was passed for 50 passages through the Vero Cell Line (monkey Kidney) at 26.degree. C. At the end of this treatment, it had become attenuated so that a vaccine formed from the virus gave none of the usual ERP symptoms when horses were inoculated with the vaccine by the I. M. route, i.e., they showed none of the usual nasal and ocular discharges, no fever, no anorexia and the like. When the vaccinates were challenged with virulent virus, none of the clinical symptoms of Equine Rhinopneumonitis Virus appeared, while unvaccinated control animals, so challenged, contracted ERP within 3-4 days with all the classical symptoms.
The vaccination of a mare prior to breeding and again during her pregnancy will prevent abortions caused by virulent ERP virus. Other horses should be vaccinated once a year in order to prevent the Equine Rhinopneumonitis disease complex. Foals may be vaccinated any time after 1 day of age even in the face of maternal antibody. The ERP Vaccine Virus may be administered parenterally or extra-parenterally to the mucosal surfaces of the body. The I. M. route of inoculation is recommended.

REFERENCES:
patent: 3725542 (1973-04-01), Mayr et al.

Affiliated with

Also associated with

Rating

Equine Rhinopneumonitis Virus does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Equine Rhinopneumonitis Virus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Equine Rhinopneumonitis Virus will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1633303